ATE133336T1 - Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen - Google Patents

Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen

Info

Publication number
ATE133336T1
ATE133336T1 AT92112716T AT92112716T ATE133336T1 AT E133336 T1 ATE133336 T1 AT E133336T1 AT 92112716 T AT92112716 T AT 92112716T AT 92112716 T AT92112716 T AT 92112716T AT E133336 T1 ATE133336 T1 AT E133336T1
Authority
AT
Austria
Prior art keywords
rapamycin
treatment
production
medicinal product
eye inflammation
Prior art date
Application number
AT92112716T
Other languages
English (en)
Inventor
Prasad Shrikrishna Kulkarni
Original Assignee
Univ Louisville Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found filed Critical Univ Louisville Res Found
Application granted granted Critical
Publication of ATE133336T1 publication Critical patent/ATE133336T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT92112716T 1991-07-25 1992-07-24 Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen ATE133336T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73560491A 1991-07-25 1991-07-25

Publications (1)

Publication Number Publication Date
ATE133336T1 true ATE133336T1 (de) 1996-02-15

Family

ID=24956475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92112716T ATE133336T1 (de) 1991-07-25 1992-07-24 Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen

Country Status (20)

Country Link
US (1) US5387589A (de)
EP (1) EP0532862B1 (de)
JP (1) JP2568962B2 (de)
KR (1) KR100216768B1 (de)
AT (1) ATE133336T1 (de)
AU (1) AU653415B2 (de)
CA (1) CA2074641C (de)
CZ (1) CZ285660B6 (de)
DE (1) DE69207847T2 (de)
DK (1) DK0532862T3 (de)
ES (1) ES2083030T3 (de)
HK (1) HK1005705A1 (de)
HU (1) HU211218B (de)
IE (1) IE922430A1 (de)
IL (1) IL102414A (de)
MX (1) MX9204381A (de)
NZ (1) NZ243679A (de)
RU (1) RU2048812C1 (de)
SK (1) SK280511B6 (de)
ZA (1) ZA924953B (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154262T3 (es) * 1991-04-26 2001-04-01 Fujisawa Pharmaceutical Co Uso de compuestos macrolidos para enfermedades oculares.
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
KR19990048077A (ko) * 1997-12-08 1999-07-05 전원중 인조대리석 성형품의 제조방법
JP2002503692A (ja) * 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
PT1037627E (pt) * 1998-07-14 2001-11-30 Alcon Lab Inc Utilizacao do acido 11-(3-dimetilaminopropilideno)-6,11-dihidrodibenz¬b,e|oxepin-2-acetico e seus sais derivados farmaceuticamente aceitaveis para a producao de um medicamento para o tratamento de doencas inflamatorias oftalmicas nao-alergicas e para a prebencao da neovascularizacao ocular
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2000038703A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
RU2187984C2 (ru) * 1999-02-26 2002-08-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ лечения воспалительных заболеваний глаза
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
RU2180822C2 (ru) * 1999-09-28 2002-03-27 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения заболеваний и повреждений передней поверхности глаза
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (de) 2001-08-22 2005-10-05 Wyeth Rapanycin29-enole
RU2004118424A (ru) * 2001-11-19 2005-05-10 Новартис АГ (CH) Применение аскомицина для лечения блефарита
EP1478648B1 (de) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorhaltige verbindungen und deren verwendungen
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
UA81265C2 (en) * 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
SI1539157T1 (sl) * 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
RU2232586C1 (ru) * 2003-04-23 2004-07-20 Закрытое Акционерное Общество Производственное Предприятие "Эндо-Фарм-А" Офтальмологическое лекарственное средство и способ лечения заболеваний, патологических состояний и повреждений сетчатой оболочки глаза
RU2242192C1 (ru) * 2003-06-18 2004-12-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Фармацевтическая композиция для лечения воспалительных процессов в заднем отрезке глаза "делипос"
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
RU2240107C1 (ru) * 2003-10-21 2004-11-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Гель для лечения бактериальных конъюнктивитов (варианты)
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
RU2284181C2 (ru) * 2004-11-11 2006-09-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Федерального агентства по здравоохранению и социальному развитию (ФГУ "МНТК"МГ"им. акад. С.Н. Федорова Росздрава") Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
CA2602525A1 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
EP1890652B1 (de) 2005-05-13 2017-08-02 Akkolens International B.V. Künstliche intraokularlinse für durch die iris bewirkte akkomodation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) * 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
RU2331408C1 (ru) * 2007-05-31 2008-08-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Глазная мазь
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
RU2010126096A (ru) * 2007-11-27 2012-01-10 Алькон Рисерч, Лтд. (Us) Офтальмологические или ушные препаративные формы в виде раствора для наружного применения, содержащие моксифлокцина гидрохлорид и дексаметазона фосфат
EP2352459A4 (de) * 2008-10-03 2013-09-25 Elixir Medical Corp Makrocyclische lactonverbindungen und verfahren zu ihrer verwendung
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
EP2440185B1 (de) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topische arzneimittelabgabesysteme zur ophthalmischen verwendung
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
EP3463349B1 (de) 2016-05-25 2021-08-04 Santen Pharmaceutical Co., Ltd. Verwendung von sirolimus zur behandlung von exsudativer altersbedingter makuladegeneration mit persistentem ödem
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CN109310680B (zh) 2016-06-30 2022-11-01 度瑞公司 长效配制物
CN110603038A (zh) 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3639854B1 (de) 2017-06-16 2026-01-07 The Doshisha Mtor-hemmeer zur behandlung oder vorbeugung von fuchs-endotheldystrophie
EP4082544A4 (de) 2019-12-26 2024-01-10 Santen Pharmaceutical Co., Ltd. Wässrige suspensionszusammensetzung, die sirolimus oder ein salz davon enthält

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use

Also Published As

Publication number Publication date
HUT63763A (en) 1993-10-28
HK1005705A1 (en) 1999-01-22
MX9204381A (es) 1993-02-01
KR100216768B1 (ko) 1999-09-01
DE69207847D1 (de) 1996-03-07
US5387589A (en) 1995-02-07
CA2074641A1 (en) 1993-01-26
HU9202448D0 (en) 1992-10-28
EP0532862A1 (de) 1993-03-24
JPH05194212A (ja) 1993-08-03
NZ243679A (en) 1997-06-24
CA2074641C (en) 1999-05-04
HU211218B (en) 1995-11-28
EP0532862B1 (de) 1996-01-24
IL102414A (en) 1996-08-04
RU2048812C1 (ru) 1995-11-27
JP2568962B2 (ja) 1997-01-08
IE922430A1 (en) 1993-01-27
DK0532862T3 (da) 1996-02-19
IL102414A0 (en) 1993-01-14
AU653415B2 (en) 1994-09-29
SK230792A3 (en) 1996-05-08
AU2035092A (en) 1993-01-28
DE69207847T2 (de) 1996-05-30
CZ285660B6 (cs) 1999-10-13
ZA924953B (en) 1993-04-28
CZ230792A3 (en) 1993-02-17
SK280511B6 (sk) 2000-03-13
ES2083030T3 (es) 1996-04-01
KR930001913A (ko) 1993-02-22

Similar Documents

Publication Publication Date Title
DE69207847D1 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
ATE205389T1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69427337D1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE234615T1 (de) Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren
ATE140918T1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
DE69400631D1 (de) Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE69129563D1 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ATE169226T1 (de) Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
DE3678113D1 (de) Verwendung von hyperoxygenierten oelen zur herstellung eines arzneimittells zur behandlung von herpes.
ATE183390T1 (de) Verwendung einer kombination von antineoplastonen zur herstellung eines arzneimittels zur behandlung der neurofibromatose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee